Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-04-18
2006-04-18
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S145100, C424S156100, C436S501000, C436S506000, C435S007100, C530S300000
Reexamination Certificate
active
07029676
ABSTRACT:
The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.
REFERENCES:
patent: 3652761 (1972-03-01), Weetal
patent: 4478946 (1984-10-01), Van der Merwe et al.
patent: 4554088 (1985-11-01), Whitehead et al.
patent: 5002873 (1991-03-01), St. John et al.
patent: 5120830 (1992-06-01), Santoro
patent: 5188959 (1993-02-01), Haberman
patent: 5206345 (1993-04-01), Masinovsky et al.
patent: 5211657 (1993-05-01), Yamada et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5594120 (1997-01-01), Brenner et al.
patent: 5610281 (1997-03-01), Brenner et al.
patent: 6300080 (2001-10-01), Brenner et al.
patent: 6406870 (2002-06-01), Brenner et al.
patent: WO 9107977 (1991-06-01), None
patent: WO 9529693 (1993-09-01), None
patent: WO 9411401 (1994-05-01), None
patent: WO 9522610 (1995-08-01), None
Herrenknecht et al., Characterization of recombinant E-cadherin (uvomorulin) expressed in insect cells, Journal of Science, 17:147-154 (1993).
Wheelock et al., Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion, Journal of Cellular Biochemistry, 34(3):187-202 (1987).
Katayama et al., Soluble E-cadherin fragments increased in circulation of cancer patients, British Journal of Cancer, 69(3):580-585 (1994).
Parker et al., A family of β7 integrins on human mucosal lymphocytes, (1992), Proc. Natl. Acad. Sci. USA 89:1924-1928.
Geiger et al., Cadherins, (1992), Annual Review of Cell Biology 8:307-32.
Kemler From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion, (1993) Trends in Gastroenterology 9:317-321.
Takeichi, Cadherins: A molecular family important in selective cell-cell adhesion, (1990) Annual Review of Biochem. 59:237-252.
Takeichi, Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator, (1991) Science 251:1451-1455.
Nose et al., Localization of Specificity Determining Sites in Cadherin Cell Adhesion Molecules, (1990), Cell 61:147-155.
Cepek et al., Integrin αEβ7 Mediates Adhesion of T Lymphocytes to Epithelial Cells, (1993), J. Immunol. 150, 3459-3470.
Kaiserlain et al., Expresion, function and regulation of the intercellular adhesion molecule-1 (ICAM-1) on human intestinal epithelial cell lines, (1991) Eur. J. of Immunol. 21(10): 2415-2421.
Shimoyama et al., Cadherin Cell-Adhesion Molecules in Human Epithelial Tissues and Carcinomas, (1989) Cancer Research 49(8):2128-2133.
Vestweber et al., Identification of a putative cell adhesion domain of uvomorulin, (1985) EMBO J. 4:3393-3398.
Springer, Adhesion receptors of the immune system, (1990) Nature 346(6283):425-434.
Springer, The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors, (1990) Annual Review of Cell Biol. 6:359-402.
Ferguson et al., Two integrin-binding peptides abrogate T cell-mediate immune response in vivo, Proc. Natl. Acad. Sci., USA, vol. 88:8072-8076, (Sep. 1991).
Taylor et al., A peptide corresponding to GPIIb/IIIα 300-312, a presumptive Fibrinogen -Chain binding on the Platelet Integrin GPIIbα, Inhibits the Adhesion of Platelets to at Least Four Adhesive Ligands, J. Bio. Chem.; Jun. 15, 1992; 267, 11729-11733.
Vedder et al., Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in in the rabbit ear, Proc. Natl. Acad. Sci., USA, vol. 87: 2643-2646, Apr. 1990.
Yednock et al., Prevention of experimental autoimmune encephalomvelitis by antibodies against α4β1 integrin, Nature, 356, Mar. 5, 1992:63-66.
Hochstenbach et al., Characterization of a Third Form of the Human T Cell Receptor, J. Exp. Med. 168-761-776 (1988).
Moller et al., Rapid Communication-Monoclonal Antibody HML-1, a marker for Intraepithelial T Cells and Lymphomas Derived Thereof, Also Recognizes Hairy Cell Leukemia and Some B-cell Lymphomas, Amer. J. Path, 136:509-512 (1990).
Visser et al., Monoclonal Antibodies Reactive with Hairy Cell Leukemia, Blood 74:320-325 (1989).
Cerf-Bensussan et al., A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes, Eur. J. Immunol. 17: 1279-1285 (1987).
Pallesen et al., Specificity of monoclonal antibody HML-I, Lancet 335:537 (1990).
Visser et al., Induction of B-cell chronic lymphocytic leukaemia and hairy cell leukaemia like phenotypes by phorbol ester treatment of normal peripheral blood B-cells, Brit. J. Haematol, 75:359-365 (1990).
Albelda, Biology of Disease—Role of Integrins and Other Cell Adhesion Molecules in Tumor Progression and Metastasis, Laboratory Investigation, 68: 4-17 (1993).
Cerf-Bensussan et al., The human intraepithelial lymphocyte marker HML-I is an integrin consisting of a β7 subunit associated with a distinctive α chain, Eur. J. Immunol. 22:273-277 (1992).
Krissansen et al., Immunologic and structural relatedness of the integrin β7complex and the human intraepithelial lymphocyte antigen HML-1, FEBS Letts. 296:25-28 (1992).
Leff et al., Inflammation and cell-cell interactions in airway hyperresponsiveness, Am., Physiological Soc., 186-206 (1991).
Seth et al., ICAM-2 peptides mediative lymphocyte adhesion by binding to CD11a/CD18 and CD49d/CD29 integrins, FEBS Letters 282: 193-196 (1991).
Conrad et al., A concise Review: Iron Absorption-The Mucin-Mobilferrin-Integrin Pathway, A Competitive Pathway for Metal Absorption, Am. J. Hematology, 42: 42-67 (1993).
Mette et al., Distribution of Integrin Cell Adhesion Receptors on Normal Bronchial Epithelial Cells and Lung Cancer Cells In Vitro and In Vivo, Am. J. Respir., Cell. Mol. Biol., 8:562-572 (1993).
Uhlmann et al., Antisense Oligonucleotides: A New Therapeutic Principle Chemical Reviews, vol. 90(4):543-584 (1990).
Holt et al., An Oligomer Complementary to c-myc MRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation, Mol. Cell. Biol., 8(2):963-973 (1988).
Cooney et al., Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene In Vitro, Science, vol. 241:456-459 (1988).
Helene et al., Oligodeoxynucleotides covalently linked to intercalating agents: a new class of gene regulatory substances, Biochimie, 67: 777-783 (1985).
James, Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes, Antiviral Chem. & Chemo. 2(4):191-214 (1991).
Weiss, Upping the Antisense Ante-Scientists bet on profits from reverse genetics, Science News, 139:108-109 (1991).
Arnaout et al., Molecular cloning of the α subunit of human and guinea pig leukocyte adhesion Mol: Chromosomal localization and homology to the α subunits of integrins, Proc. Natl. Acad. Sci. USA, 85:2776-2780 (1988).
Lallier et al., Inhibition of Neural Crest Cell Attachment by Integrin Antisense Oligonucleotides, Science, 259: 692-695 (1988).
Shatzman et al., Expression, Identification and Characterization of Recombinant Gene Products inEscherichia coli, Methods in Enzymology, 152: 661-673 (1986).
Roberts et al., The Mucosal T Cell Integrin Alpha-M-290-Beta-7 Recognizes a Ligand on Mucosal Epithelial Cell Lines, Eur. J. Immunol. 23(7):1630-1635 (1993).
Tidd, A Potential Rose for Antisense Oligonucleotide Analogues in the Development of Oncogene Targeted Cancer Chemotherapy, Anticancer Research 10:1169-1182 (1990).
Wu-Pong, Oligonucleotides: Opportunities for Drug Therapy and Research Pharm. Tech.: 102-114 (1994).
Westermann et al., Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides, Biomed., Bioch
Brenner Michael B.
Cepek Karyn L.
Scheiner Laurie
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for modulating heterotypic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating heterotypic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating heterotypic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587151